Results
1 -
7 of
7The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?, Cellular and Molecular Life Sciences CMLS Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors, Investigational New Drugs Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor, Investigational New Drugs